{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:05:00Z","timestamp":1778216700728,"version":"3.51.4"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can generate responses within hours or days, rather than weeks or months. These novel targets include the N-methyl-D-glutamate receptor antagonist ketamine, along with its enantiomers and various derivatives, and the allosteric modulators of gamma-aminobutyric acid (GABA) receptors. There has also been a strong resurgence in interest in psychedelic compounds that impact a range of receptor sites including D1, 5-HT7, KOR, 5-HT5A, Sigma-1, NMDA, and BDNF. The RAADs developed from these novel targets have enabled successful treatment for difficult to treat depressed individuals and has generated a new wave of innovation in research and treatment. Despite the advances in the neurobiology and clinical treatment of mood disorders, we are still using rating instruments that were created decades ago for drugs from a different era (e.g., The Hamilton and Montgomery-\u00c5sberg depression rating scales, HDRS, and MADRS) continue to be used. These rating instruments were designed to assess mood symptoms over a 7-day time frame. Consequently, the use of these rating instruments often requires modifications to address items that cannot be assessed in short time frames, such as the sleep and appetite items. This review describes the adaptative approaches that have been made with the existing scales to meet this need and examines additional domains such as daily activities, side effects, suicidal ideation and behavior, and role functioning. Recommendations for future studies are described, including the challenges related to implementation of these adapted measures and approaches to mitigation.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1135828","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T14:30:49Z","timestamp":1685716249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants"],"prefix":"10.3389","volume":"14","author":[{"given":"Christian","family":"Yavorsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Opler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Sedway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Targum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lenderking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(19)30292-5","article-title":"Food and drug administration approval of esketamine and brexanolone","volume":"12","author":"Cristea","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4088\/JCP.15m10381","article-title":"A new prediction model for evaluating treatment-resistant depression","volume":"78","author":"Kautzky","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1017\/S1092852914000686","article-title":"Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish","volume":"21","author":"Opler","year":"2016","journal-title":"CNS Spectr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress."},{"key":"B6","author":"Dittrich","year":"2010","journal-title":"5D.-ASC: Questionnaire for the Assessment of Altered States of Consciousness"},{"key":"B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry."},{"key":"B8","volume-title":"Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness","author":"Pahnke","year":"1963"},{"key":"B9","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int Psychiatry Clin."},{"key":"B10","doi-asserted-by":"publisher","first-page":"710338","DOI":"10.3389\/fpsyt.2021.710338","article-title":"An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: improving therapeutic outcomes with treatment resistant depression","volume":"12","author":"Muscat","year":"2021","journal-title":"Front Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","article-title":"Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety","volume":"15","author":"Davis","year":"2020","journal-title":"J Contextual Behav Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","article-title":"A structured interview guide for the Hamilton Depression Rating Scale","volume":"45","author":"Williams","year":"1988","journal-title":"Arch Gen Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery \u00c5sberg Depression Rating Scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry."},{"key":"B19","volume-title":"The Anxiety Disease and How to Overcome It.","author":"Sheehan","year":"1983"},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B22","article-title":"Comparative validation of the S-STS, the ISST-Plus, and the C\u2013SSRS for assessing the suicidal thinking and behavior FDA 2012 suicidality categories","author":"Sheehan","year":"2014","journal-title":"Innov Clin Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1176\/appi.ajp.161.12.2163","article-title":"The Hamilton Depression Rating Scale: has the gold standard become a lead weight?","volume":"161","author":"Bagby","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B24","first-page":"66","article-title":"The Columbia-Suicide Severity Rating Scale (C\u2013SSRS): Has the \u201cgold standard\u201d become a liability?","volume":"11","author":"Giddens","year":"2014","journal-title":"Innov Clin Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","article-title":"Molecular pharmacology and neurobiology of rapid-acting antidepressants","volume":"59","author":"Gould","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/acps.13216","article-title":"The effects of ketamine on typical and atypical depressive symptoms","volume":"142","author":"Park","year":"2020","journal-title":"Acta Scandan."},{"key":"B27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum Psychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.ajp-rj.2017.120302","article-title":"Ketamine as a rapid-acting antidepressant: promising clinical and basic research","volume":"12","author":"Tuck","year":"2017","journal-title":"Am J Psychiatry Resid J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.4088\/JCP.15m10253","article-title":"Evidence to support Montgomery-\u00c5sberg depression rating scale administration every 24 hours to assess rapid onset of treatment response","volume":"77","author":"Johnson","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S476","DOI":"10.1038\/npp.2017.266","article-title":"Can the MADRS measure rapid changes in depressive symptoms in response to esketamine treatment?","volume":"42","author":"Yavorsky","year":"2017","journal-title":"Neuropsychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1017\/S1461145711000927","article-title":"Rapid-acting antidepressant strategies: mechanisms of action","volume":"15","author":"Bunney","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jpsychires.2014.12.015","article-title":"Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales","volume":"61","author":"Luckenbaugh","year":"2015","journal-title":"J Psychiatr Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2013211","DOI":"10.1001\/jamanetworkopen.2020.13211","article-title":"Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: A randomized clinical trial","volume":"3","author":"Milak","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000457131","article-title":"Systematic review of the clinimetric properties of the 6-item version of the hamilton depression rating scale (HAM-D6)","volume":"86","author":"Timmerby","year":"2017","journal-title":"Psychother Psychosom"},{"key":"B36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-0447.1997.tb09649.x","article-title":"Sensitivity of the six-item Hamilton Depression Rating Scale","volume":"95","author":"O'Sullivan","year":"1997","journal-title":"Acta Psychiatr Scand."},{"key":"B37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41386-019-0545-y","article-title":"NV-5138 a novel, direct activator of the mechanistic target of rapamycin complex 1 (mTORC1): a phase 1b randomized, double-blind, placebo-controlled single oral dose study in subjects with treatment-resistant depression (TRD)","volume":"44","author":"Targum","year":"2019","journal-title":"Am Coll Neuropsychopharmac."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jad.2021.07.035","article-title":"The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine","volume":"294","author":"McIntyre","year":"2021","journal-title":"J Affect Disord."},{"key":"B40","doi-asserted-by":"publisher","first-page":"110126","DOI":"10.1016\/j.pnpbp.2020.110126","article-title":"Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence","volume":"105","author":"Lipsitz","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B41","article-title":"\u201cReliability, validity, and responsiveness of the QIDS-SR16 daily version,\u201d In: 12th Annual International Society Of Quality-Of-Life Research Annual Meeting","author":"Lenderking","year":""},{"key":"B42","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.cct.2008.05.012","article-title":"Daily process methodology for measuring earlier antidepressant response","volume":"29","author":"Lenderking","year":"2008","journal-title":"Contemp Clin Trials."},{"key":"B43","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jad.2020.11.066","article-title":"Meaningful change in depression symptoms assessed with the patient health questionnaire (PHQ-9) and Montgomery-\u00c5sberg depression rating scale (MADRS) among patients with treatment resistant depression in two, randomized, double-blind, active-controlled trials of esketamine nasal spray combined with a new oral antidepressant","volume":"281","author":"Hudgens","year":"2021","journal-title":"J Affect Disord."},{"key":"B45","first-page":"237","article-title":"Chapter Eight: relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants","volume-title":"Advances in Pharmacology.","author":"Singh","year":"2020"},{"key":"B46","doi-asserted-by":"publisher","first-page":"101439","DOI":"10.1016\/j.eclinm.2022.101439","article-title":"Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: a retrospective case series","volume":"48","author":"Artin","year":"2022","journal-title":"EClinicalMedicine."},{"key":"B47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/ijnp\/pyac049","article-title":"Predicting antidepressant effects of ketamine: The role of the pregenual anterior cingulate cortex as a multimodal neuroimaging biomarker","volume":"25","author":"Weigand","year":"2022","journal-title":"Int J Neuropsychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0304-3959(85)90137-X","article-title":"Psychology Estimating levels of subjectively experienced states on DISCAN Scales by RCS: A repeated comparison system","volume":"23","author":"Singh","year":"1985","journal-title":"Pain"},{"key":"B50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40271-015-0132-1","article-title":"Patient-centered research to support the development of the symptoms of major depressive disorder scale (SMDDS): initial qualitative research","volume":"9","author":"McCarrier","year":"2016","journal-title":"Patient."},{"key":"B51","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2019.02.010","article-title":"Symptoms of major depressive disorder scale: performance of a novel patient-reported symptom measure","volume":"22","author":"Bushnell","year":"2019","journal-title":"Value Health."},{"key":"B52","year":"2021","journal-title":"FDA Clinical Outcome Assessments (COA) Qualification Program Submissions Page"},{"key":"B53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jad.2021.03.053","article-title":"Validation of the McIntyre and rosenblat rapid response scale (MARRRS) in adults with treatment-resistant depression receiving intravenous ketamine treatment","volume":"288","author":"McIntyre","year":"2021","journal-title":"J Affect Disord."},{"key":"B54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e02077","DOI":"10.1002\/brb3.2077","article-title":"Estimating longitudinal depressive symptoms from smartphone data in a transdiagnostic cohort","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Brain Behav."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibmed.2020.100006","article-title":"Machine learning for ambulatory applications of neuropsychological testing","author":"Chandler","year":"2020","journal-title":"Intell Based Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"610006","DOI":"10.3389\/fdgth.2021.610006","article-title":"Remote digital measurement of facial and vocal markers of major depressive disorder severity and treatment response: A pilot study","volume":"3","author":"Anzar","year":"2021","journal-title":"Front Digit Health."},{"key":"B58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11920-019-1043-y","article-title":"Smartphone-based tracking of sleep in depression, anxiety, and psychotic disorders","volume":"21","author":"Aledavood","year":"2019","journal-title":"Curr Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5498\/wjp.v12.i3.393","article-title":"Digital phenotyping in depression diagnostics: integrating psychiatric and engineering perspectives","volume":"12","author":"Kamath","year":"2022","journal-title":"World J Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jpsychires.2021.02.012","article-title":"Ecological momentary assessment as a measurement tool in depression trials","volume":"136","author":"Targum","year":"2021","journal-title":"J Psychiatr Res."},{"key":"B61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.18653\/v1\/2020.nlpmc-1.7","article-title":"On the utility of audiovisual dialog technologies and signal analytics for real-time remote monitoring of depression biomarkers","volume-title":"Proceedings of the First Workshop on Natural Language Processing for Medical Conversations.","author":"Neumann","year":"2020"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1135828\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T14:31:02Z","timestamp":1685716262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1135828\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":61,"alternative-id":["10.3389\/fpsyt.2023.1135828"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1135828","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1135828"}}